Google Alert - "Myeloproliferative neoplasms" OR "polycythemia vera" OR myelofibrosis OR "essential thrombocythemia" · Scour

25-year-long study discovers how blood cancers evolve and worsen

Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036

Ruxolitinib/Abemaciclib Shows Encouraging Efficacy in Myelofibrosis

Optimizing Treatment Outcomes in Polycythemia Vera

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral ...

Leading Companies Fueling Innovation and Growth in the Myelofibrosis (MF) Market

Mocertatug Rezetecan Shows Promising Efficacy, Manageable Safety in Ovarian and ...

Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of ...

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral ...

IL-6, hepcidin, and the hidden driver of anemia in MF: Are you targeting the right pathway?

Why JAK inhibitors worsen anemia in myelofibrosis —and how one agent changes the equation

Karyopharm's myelofibrosis trial selected for ASCO presentation By Investing.com

Disc Medicine, Inc. to Present RALLY-MF Trial Data on DISC-0974 at ASCO Annual Meeting 2026

De Pere superintendent to step down over health concerns

Disc Medicine to present myelofibrosis trial data at ASCO meeting

KPTI phase 3 myelofibrosis trial selected for ASCO presentation

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral ...

Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 ...

Disc Medicine announced that the Phase 2 clinical trial data of its drug DISC-0974 in ...

Disc Medicine ASCO oral slot for DISC-0974 MF data | IRON Stock News

Log in to enable infinite scrolling